Clinical usefulness of fluorescence in situ hybridization for diagnosis and surveillance of bladder cancer

Cancer Genetics and Cytogenetics

Volumn 198, Issue 2, 2010, Pages 144-150

  Song, Min Jung ^a   Lee, Hyun Moo ^a   Kim, Sun Hee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INVASION; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE CYTOLOGY;

AGED; BIOPSY; CARCINOMA; CHROMOSOME ABERRATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 77950837749     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.01.007     Document Type: Article

References (21)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Amira N., Mourah S., Rozet F., Teillac P., Fiet J., Aubin P., Cortesse A., Desgrandchamps F., Le Duc A., Cussenot O., Soliman H. Non-invasive molecular detection of bladder cancer recurrence. Int J Cancer 2002, 101:293-297.
3. Wiener H.G., Mian C., Haitel A., Pycha A., Schatzl G., Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?. J Urol 1998, 159:1876-1880.
4. Maier U., Simak R., Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 1995, 48:314-317.
5. Balázs M., Carroll P., Kerschmann R., Sauter G., Waldman F.M. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 1997, 19:84-89.
6. Zhao J., Richter J., Wagner U., Roth B., Schraml P., Zellweger T., Ackermann D., Schmid U., Moch H., Mihatsch M.J., Gasser T.C., Sauter G. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res 1999, 59:4658-4661.
7. Zellweger T., Benz G., Cathomas G., Mihatsch M.J., Sulser T., Gasser T.C., Bubendorf L. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006, 119:1660-1665.
8. Marin-Aguilera M., Mengual L., Ribal M.J., Burset M., Arce Y., Ars E., Oliver A., Villavicencio H., Algaba F., Alcaraz A. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogenet 2007, 173:131-135.
9. Yoder B.J., Skacel M., Hedgepeth R., Babineau D., Ulchaker J.C., Liou L.S., Brainard J.A., Biscotti C.V., Jones J.S., Tubbs R.R. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007, 127:295-301.
10. Seitz M., Zaak D., Knüchel-Clarke R., Stief C. Urinary bladder tumors: the new 2004 WHO classification [In German]. Urologe A 2005, 44:1073-1086.
11. Sokolova I.A., Halling K.C., Jenkins R.B., Burkhardt H.M., Meyer R.G., Seelig S.A., King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000, 2:116-123.
12. Halling K.C., King W., Sokolova I.A., Karnes R.J., Meyer R.G., Powell E.L., Sebo T.J., Cheville J.C., Clayton A.C., Krajnik K.L., Ebert T.A., Nelson R.E., Burkhardt H.M., Ramakumar S., Stewart C.S., Pankratz V.S., Lieber M.M., Blute M.L., Zincke H., Seelig S.A., Jenkins R.B., O'Kane D.J. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002, 167:2001-2006.
13. Bubendorf L., Grilli B., Sauter G., Mihatsch M.J., Gasser T.C., Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001, 116:79-86.
14. Junker K., Fritsch T., Hartmann A., Schulze W., Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006, 114:279-283.
15. Steidl C., Simon R., Bürger H., Brinkschmidt C., Hertle L., Böcker W., Terpe H.J. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol 2002, 198:115-120.
16. Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. Histol Histopathol 2003, 18:259-274.
17. Gofrit O.N., Zorn K.C., Silvestre J., Shalhav A.L., Zagaja G.P., Msezane L.P., Steinberg G.D. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008, 26:246-249.
18. Bollmann M., Heller H., Bánkfalvi A., Griefingholt H., Bollmann R. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?. BJU Int 2005, 95:1219-1225.
19. Riesz P., Lotz G., Páska C., Szendrôi A., Majoros A., Németh Z., Törzsök P., Szarvas T., Kovalszky I., Schaff Z., Romics I., Kiss A. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 2007, 13:187-194.
20. Lotan Y., Bensalah K., Ruddell T., Shariat S.F., Sagalowsky A.I., Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008, 179:2164-2169.
21. Mengual L., Marín-Aguilera M., Ribal M.J., Burset M., Villavicencio H., Oliver A., Alcaraz A. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy. Eur Urol 2007, 52:752-759.